Inovio Pharma (INO) Misses Q3 EPS by 14c
Tweet
Share
E-mailGet Alerts INO Hot Sheet
Price: $10.50 -5.15%
Revenue Growth %: +490.9%
Financial Fact:
Loss from investment in affiliated entity: -958.14K
Today's EPS Names:
ESCA, LICT, NKSH, More
Revenue Growth %: +490.9%
Financial Fact:
Loss from investment in affiliated entity: -958.14K
Today's EPS Names:
ESCA, LICT, NKSH, More
Join SI Premium – FREE
Inovio Pharma (NASDAQ: INO) reported Q3 EPS of ($0.39), $0.14 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $2.6 million versus the consensus estimate of $9.36 million.
For earnings history and earnings-related data on Inovio Pharma (INO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Iridium Communications (IRDM) Reports In-Line Q1 EPS; offers outlook
- D. R. Horton (DHI) Tops Q2 EPS by 45c, offers guidance
- Badger Meter (BMI) Tops Q1 EPS by 17c ; Provides Outlook
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
